Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Immunic Begins IMU-838, Oseltamivir Trial for COVID-19

americanpharmaceuticalreviewJuly 31, 2020

Tag: Immunic , IMU-838 , COVID-19 , oseltamivir

PharmaSources Customer Service